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Purpose: Ridaforolimus (AP23573, MK-8669 or deforolimus) is an inhibitor of mammalian target of rapamycin
(mTOR), an important regulator in the cell survival pathway. This open-label, single center phase I study aimed to
investigate the pharmacokinetic (PK) and safety profiles of ridaforolimus in Chinese patients with treatment-refractory
advanced or relapsed solid tumors. The PK data generated from these Chinese patients were further compared with
those previously reported in Caucasian and Japanese patient populations.
Experimental design: The patients were given an oral dose of 40 mg of ridaforolimus on Day 1 of the study. On Day
8, patients were initiated on a treatment regimen that comprised a once daily dose of 40 mg of ridaforolimus for five
consecutive days, followed by a 2-day off-drug interval. Patients repeated this regimen until disease progression or
intolerance. Blood samples were collected at specific times pre- and post-treatment to establish the PK profile of
ridaforolimus in all patients.
Results: Fifteen patients were given at least one dose of 40 mg of ridaforolimus. The median absorption lag-time was
2 hours, the median Tmax was 4 hours and the mean elimination half-life was 53 hours. The accumulation ratio for
AUC0-24hr was 1.3 on day 19 (steady state)/day 1 (after a single dose). The most common drug-related adverse events
(AEs) that occurred in ≥40% of patients were stomatitis, proteinuria, leukopenia, hyperglycemia, and pyrexia. Grade 3/4
drug-related AEs were anemia, stomatitis, fatigue, thrombocytopenia, constipation, gamma glutamyltransferase
increase, and proteinuria. All 11 evaluable patients achieved stable disease.
Conclusions: Oral ridaforolimus at a daily dose of 40 mg were generally well tolerated in Chinese patients with
advanced or refractory solid tumors. Adverse events and PK profiles of ridaforolimus in this study were similar to those
from Caucasian and Japanese patients reported previously.
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Mammalian target of rapamycin is a serine/threonine
kinase that fulfills a pivotal role in regulating cell growth
and proliferation. Together with the phosphatidylinositol-
3-kinase (PI3K)-AKT transduction pathway, mTOR forms
a signaling network that has been implicated in various
types of cancer [1]. This signaling network is considered a
validated target for innovative cancer therapy and therefore
mTOR inhibitors are thought to have potent antitumor* Correspondence: fudanlijin@163.com
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reproduction in any medium, provided the oractivity [2-5]. Active signaling via mTOR requires forma-
tion of the ternary complex mTOR Complex-1 and mTOR
Complex-2. Activity of mTOR complex-1 can be inhibited
by rapamycin and several rapamycin analogs have been
developed to serve as potential antitumor agents.
Ridaforolimus (Merck & Co., Inc. Whitehouse Station,
NJ, USA) is a non-prodrug analog of rapamycin and
pre-clinical studies showed its anti-tumor activity in a
wide variety of cancers [6]. Furthermore, phase II clinical
trials with ridaforolimus as monotherapy showed good
tolerability as well as clinical activity in prostate cancer [7],
in bone and soft tissue sarcomas [8], and in hematologic
malignancies [9]. In a phase III trial, as maintenance
therapy, ridaforolimus significantly improved progressionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with advanced sarcoma who had clinical benefit
from prior standard cytotoxic chemotherapy (P = 0.0001;
median PFS: 17.7 weeks vs 14.6 weeks for ridaforolimus
and a placebo, respectively). Median overall survival at
data cut-off (386 deaths), was 93.3 weeks in patients
given ridaforolimus vs 83.4 weeks in patients given a
placebo (P = 0.23) [10].
The safety, tolerability, and pharmacokinetics (PK) of
oral ridaforolimus have been investigated previously in
Caucasians and Japanese patients, the most important dose
limiting toxicity is stomatitis, and the oral dose of 40mg per
day for five consecutive days followed by two day's off was
well tolerated [11-14]. As PK could be different between
Chinese population and Japanese population, this phase I
trial was designed to evaluate the safety, tolerability and PK
of oral ridaforolimus in Chinese patients with treatment-
refractory advanced or relapsed solid tumors.
Methods
Patients
Chinese patients older than 18 years of age with histologi-
cally or cytologically proven metastatic or locally advanced
solid tumor(s), who progressed on standard therapy, or
for whom standard therapy does not exist, were eligible
for enrolment. Inclusion criteria also included Eastern
Cooperative Oncology Group (ECOG) performance
status of ≤1, acceptable hematologic, hepatic, and renal
function with absolute neutrophil count ≥1,500/μL,
platelet count ≥100,000/μL, hemoglobin level ≥9.0 g/dL,
serum creatinine level ≤1.5 mg/dL or creatinine clear-
ance ≥60 mL/min, total bilirubin level within normal
range, aspartate aminotransferase and alanine amino-
transferase level ≤2.5 × upper limits of normal, total
cholesterol ≤350 mg/dL, triglycerides ≤400 mg/dL, and
hemoglobin A1C < 8%. Patients also had to have a life
expectancy of more than three months.
Exclusion criteria included chemo-, radio-, or biological-
therapy within four weeks prior to enrolment; primary or
unstable central nervous system metastasis; clinically sig-
nificant abnormality on electrocardiogram; and New York
Heart Association Class III or IV congestive heart failure
or any other significant history of cardiac disease.
Ethics
The study was approved by the institutional review
board of the Fudan University Shanghai Cancer Center
Ethics Committee and conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice.
All patients provided written informed consent.
Study design
This was an open-label, single-center PK study of
ridaforolimus (clinicaltrials.gov registration, NCT01380184).The treatment dose of 40 mg of ridaforolimus per day was
based on the results of previous phase I clinical studies that
investigated various dosing schedules for ridaforolimus in
non-Chinese patients (internal data).
The eligible patients were given the following treatment
regimen: a single oral dose of 40 mg of ridaforolimus on
Day 1; and then, the treatment started from Day 8 with an
oral dose of 40 mg of ridaforolimus for five consecutive
days (on Day 8 through Day 12) followed by two day's off
(Day 13 and 14). The treatment repeated every 7 days.
Four treatment weeks was considered one treatment
cycle. Sample blood for PK analysis were collected at
the following times: on Day 1 prior to drug administra-
tion and for 168 h post-dose (at 1, 2, 3, 4, 6, 8, 24, 72,
96, and 168 h post-treatment); on Day 8 and Day 15
prior to drug administration; on Day 19 prior to drug
administration and for 24 h post-dose (at 1, 2, 3, 4, 6, 8
and 24 h post-treatment). We monitored patients’ vital
signs and conducted laboratory and physical examinations
on trial Day 1, 8 and 19.
The patients continued to receive 40 mg of ridaforolimus
for five consecutive days followed by two day's off until dis-
ease progression or intolerability. Averse events were moni-
tored every four weeks and AEs were graded according to
the Common Terminology Criteria for Adverse Events
version 4.0. We also monitored patients’ vital signs and
conducted laboratory and physical examinations every four
weeks. Radiographic studies for disease assessment were
conducted at baseline and again after every two treatment
cycles (thus, every eight weeks). Tumor responses were
assessed according to the Response Evaluation Criteria for
Solid Tumors 1.1 guidelines. We conducted a full safety as-
sessment in all patients four weeks after the administration
of the last treatment dose.
Pharmacokinetic assessment
Ridaforolimus concentration in both whole blood and
plasma was analyzed using high-performance liquid
chromatography with tandem mass spectrometric detec-
tion set at a lower limit of quantification of 0.2 ng/mL
(Wuxi AppTec, Shanghai, China). Pharmacokinetic ana-
lyses were performed with WinNonlin, version 5.2.1
(Pharsight Corp., St. Louis, MO, USA). AUC0-∞, AUC0-24hr,
C24hr, and Cmax were determined for each patient on Day 1
and on Day 19, if applicable, and the geometric means as
well as the 95% CI were calculated. The accumulation of
ridaforolimus was assessed for Cmax and for AUC0-24hr
(geometric mean ratio Day 19 / Day 1 and 90% CI).
Statistical analysis
In accordance with Chinese State Food and Drug
Administration guidelines, at least 8–12 evaluable patients
should be recruited. It was estimated that 15–16 patients
were required to ensure that PK data would be obtained
Table 1 Baseline characteristics of participants
Characteristics N = 15
Median age (range, years) 51.3 (27–71)
Age group, years, n (%)
49 and Under 7 (46.7)
50 to 59 4 (26.7)




ECOG performance status n (%)
0 3 (20)
1 12 (80)
Tumor type, n (%)
Esophageal cancer 1 (6.7)
Gastric cancer 2 (13.3)
Colon cancer 5 (33.3)
Rectum cancer 2 (13.3)
Breast cancer 3 (20.0)
Soft tissue sarcoma 2 (13.3)
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Between July 14, 2011 and September 29, 2011, sixteen
patients were enrolled. Fifteen received ridaforolimus,
one patient withdrew consent before administration of

































Figure 1 Blood concentration profiles (arithmetic mean +/− SD) of ridafo
once daily dosages of 40 mg of ridaforolimus in Chinese patients with adin Table 1. The median age of patients was 51.3 years
(range, 27–71); 80% of the patients had an ECOG per-
formance status 1 and the rest had a status of 0. The
most common tumor types were colon and breast cancer
(33% and 20% respectively). Eight patients discontinued
treatment because of progressive disease, six patients
discontinued because of AEs, and one patient was lost
to follow-up.
Pharmacokinetic analysis
Figure 1 shows the time profiles of whole blood concen-
trations of ridaforolimus on Day 1 (post single dose) and
Day 19 (post multiple dosages). Table 2 summarizes the
PK parameters of ridaforolimus in whole blood.
After a single oral dose of ridaforolimus on Day 1,
quantifiable drug levels were observed after a median
absorption lag time of 2.00 h (Tlag, range: 0.97–8.07 h).
Peak concentrations occurred after a median time of
4.03 h (Tmax, range: 2.00–7.97 h). The geometric mean
AUC0-∞ was 3648 ng · h/mL (CV 34.3%). The elimin-
ation half-life (t½) was 52.9 h (CV 24%). There was large
between-patient variability see (Figure 1).
The geometric mean values for Cmax were 210 and
167 ng/mL and median values were 192 and 203 ng/mL
on Day 1 and Day 19, respectively. The geometric
mean AUC0-24hr was 1846 and 2014 ng · h/mL on Day
1 and Day 19, respectively. The accumulation ratio for
Day 19 (steady state) / Cmax on Day 1 (single dose) was
1.1 (90% CI 0.8–1.4) for Cmax and 1.3 (90% CI 1.0–1.6)
for AUC0-24hr.
Safety evaluation
A once a day oral dose of 40 mg of ridaforolimus was
generally well tolerated. Four patients (26.7%) developedme (hr)
12 16 20 24
Day 1
Day 19
0 24 48 72 96 120 144 168
rolimus following administration of a single oral dose or multiple
vances or metastatic solid tumors (Day 1 n = 15 and Day 19 n= 13).
Table 2 Pharmacokinetic parameters for ridaforolimus
following a single oral dose or multiple once daily oral
dosages of 40 mg of ridaforolimus in Chinese patients
with advanced or metastatic solid tumors
Pharmacokinetic parameter Ridaforolimus
N Mean‡ 95% CI‡
Day 1*
Tlag (hr) 15 2.00 (0.97, 8.07)
AUC0-24 (ng.hr/ml)
† 13 1846 (1361, 2503)
AUC0-∞ (ng.hr/ml) 13 3648 (3044, 4372)
Cmax (ng/ml)
† 13 210 (150, 295)
C24hr (ng/ml)
† 15 34.8 (26.0, 46.8)
Tmax (hr) 13 4.03 (2.00, 7.97)
Apparent t1/2 (hr) 15 52.9 (40.2, 65.6)
Day 19**
AUC0-24 (ng.hr/ml)
† 13 2014 (1485, 2731)
Cmax (ng/ml)
† 13 167 (119, 234)
C24hr (ng/ml)
† 13 49.7 (36.4, 67.7)
Tmax (hr) 13 4.00 (0.00, 6.00)
†Back-transformed least-squares mean and confidence interval from a linear
mixed-effect model, containing a fixed effect for day and a random effect for
subject, performed on natural log-transformed values.
‡Geometric Mean and back-transformed 95% CI for AUC0-24hr, AUC0-∞, Cmax,
and C24hr. Harmonic Mean and jackknife SD for T1/2. Median and Range
(Min, Max) for Tlag and Tmax.
*Both for Day 1 and Day 19 no samples were taken between 8 hr and 24 hr
post dose. However, for some patients no concentration levels above the
lower limit of quantification could be obtained until 8 hr post dose on Day 1.
Consequently some PK parameters could not be calculated for these patients.
In addition, Tlag was presented for all patients on Day 1.
**Two subjects were not evaluable for PK on Day 19 due to AE-related
dose reduction.
Table 3 Most common (>20%) non-serious adverse events




White blood cell count decrease 8, 53.3%
Hyperglycaemia 7, 46.7%
Pyrexia 6, 40%
Gamma-glutamyltransferase increased 6, 40%
Anemia 5, 33.3%
Platelet count decrease 5, 33.3%
Hypoalbuminaemia 5, 33.3%
Blood cholesterol increased 5, 33.3%
Fatigue 4, 26.7%
Blood alkaline phosphatase increased 4, 26.7%
ALT increase 3, 20%
Interstitial lung disease 3, 20%
Table 4 Grade 3/4 non-serious adverse events





Platelet count decrease 1/15, 6.7%
Constipation 1/15, 6.7%




Platelet count decrease 1/15, 6.7%
Liu et al. Journal of Hematology & Oncology 2013, 6:48 Page 4 of 6
http://www.jhoonline.org/content/6/1/48serious AEs. All four serious adverse events were consid-
ered as a result of progression of malignant disease, and
were not considered drug-related by the investigator.
Two of them died from uncontrollable plural effusion,
one from obstructive jaundice. Another patient devel-
oped apnea caused by the collapse of the tracheal which
was infiltrated massively by fibrosarcoma. Six patients
discontinued treatment as a result of AEs and five of these
patients discontinued due to drug-related AEs: three as a
result of drug-related interstitial lung disease, one as a re-
sult of drug-related fatigue, and another one as a result of
drug-related stomatitis. One patient discontinued due to
apnea cause by collapse of the tracheal which was defined
as serious AE described previously.
A total of 135 non-serious AEs were reported by the
fifteen patients; 111 of these AEs were deemed by the
investigator as drug related. Table 3 lists the most
commonly reported AEs (>20% incidence). Of the 135Table 5 Comparison of PK parameters between Chinese,
Caucasian and Japanese patients
PK parameters Chinese Caucasian Japanese
Single dose
AUC0-24 (ng.hr/ml)
a 1846 (1361, 2503) 992(801, 1230) 1,470 (914, 2,360)
Cmax (ng/ml)a 210 (150, 295) 112(84.6, 148) 187 (115, 304)
Tmax (hr)b 4.03 (2.00, 7.97) 2.79(1.42, 9.78) 4.00 (4.00, 8.00)
t1/2 (hr) 52.9 (40.2, 65.6)
c 42.0(17.7)d 55.8 (50.95, 60.65)c
Multiple dose
AUC0-24 (ng.hr/ml) 2014 (1485, 2731) 1882(1630, 2180) 2,120 (1,320, 3,410)
Cmax (ng/ml) 167 (119, 234) 160(136, 188) 188 (116, 306)
Tmax (hr) 4.00 (0.00, 6.00) – 4.04 (4.00, 8.15)
Accumulation ratioe
AUC0-24 1.3(1.0, 1.6) 1.90(1.63, 2.21) 1.44 (1.05, 1.99)
Cmax 1.1(0.8, 1.4) 1.43(1.22, 1.68) 1.01 (0.674, 1.50)
aGeometric mean (95% confidence interval), bMedian (min, max), cHarmonic mean
(jack-knife SD), dHarmonic mean (pseudo SD), eGeometric mean ratio
(90% confidence interval).
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Grade 1 or 2, 11 were considered to be Grade 3, and 2
were considered to be Grade 4 in severity. Grade 3/4
AEs are listed in Table 4.
Efficacy analysis
The mean duration of ridaforolimus treatment was 9.6
weeks (range, 0.2–22 weeks). Eleven patients had been
evaluated for efficacy, all of them achieved stable disease
as best efficacy, including one patient with esophageal
cancer, two with gastric cancer, four with colon cancer,
two with rectal cancer, one with breast cancer, and one
with fibrosarcoma.
Discussion
The primary objective of this phase I trial was to investigate
the PK profiles as well as the tolerability of ridaforolimus
in Chinese patients with advanced solid tumors. The
daily oral dose of 40 mg of ridaforolimus was based on
the results of previous phase I clinical studies, which
investigated various dosing schedules in non-Chinese
patients (internal data).
Although there was moderate-high variability between
patients, our results show that, in general, ridaforolimus
was slowly absorbed after oral administration. The
AUC0-24hr at steady state (Day 19, 2014 ng · h/mL) was
lower than AUC0-∞ after single dose administration
(Day 1, 3648 ng · h/mL), indicating that the blood PKs
of ridaforolimus in our patients were non-linear. It is
considered due to saturable binding of ridaforolimus to
FK506 binding protein. With regard to drug interactions,
all medications that were known to affect the CYP3A4
metabolism of ridaforolimus were discontinued before
administration of ridaforolimus. Concomitant medications
which may affect the pH of the stomach (e.g., antacids)
are thought unlikely to have an effect on ridaforolimus PK
due to drug solubility but could affect the dissolution of
the enteric coated tablet.
The PK profiles of ridaforolimus in our group of Chinese
patients did not differ from the PK data reported for
Japanese [13] or Caucasian patients with advanced solid
tumors from the internal PK data (Table 5).
Amongst Chinese patients, the most common AE was
stomatitis (12 patients, 80%), which was similar to the
results of previous studies in non-Chinese populations.
In our study, stomatitis occurred soon after initiation of
ridaforolimus. In most patients, stomatitis could be
alleviated by short treatment interruption. One patient
discontinued the study due to stomatitis. Proteinuria
(11 patients, 73.3%) was reported more often in this study
than in non-Chinese populations [11-13]. Three patients
developed Grade 2 interstitial pneumonitis, but all recov-
ered after interruption of ridaforolimus and treatment with
glucocorticoids. Mechanism-induced elevations in serumglucose, cholesterol and triglycerides are known to occur
with mTOR inhibitors, including ridaforolimus [11-14].
Summary statistics for changes from baseline over time
shown no clinically significant elevations in serum choles-
terol, serum glucose, or serum triglycerides; however, an
elevation in these three parameters was observed from
baseline after ridaforolimus dosing in this study.
Eleven of 15 patients achieved stable of disease in this
study. Although preliminary results are encouraging, the
absence of partial or complete responses indicates that
ridaforolimus might provide disease control rather than
tumor shrinkage in the patients with chemo-refractory
tumors. As reported before, objective response rates
with rapamycin derivatives have been low in most tumor
types [15,16]. A biomarker finding strategy could be
considered as an effective way to select the possible
candidates for ridaforolimus treatment. The identification
of active status of the PI3K–AKT–mTOR pathway may
be helpful to define the subgroups population potentially
sensitive to mTOR inhibitors.
In conclusion, our results show that the overall PK
and safety profile of ridaforolimus in Chinese patients
with advanced solid tumors are generally consistent with
that reported in non-Chinese patients with refractory or
advanced solid tumors. The adverse effects of ridaforolimus
were moderate and acceptable.
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